PCDHB5

Across TCGA pan-cancer cohorts, PCDHB5 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated PCDHB5 data layer compared with 11 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PCDHB5 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHB5 expression acts as an unfavorable survival marker, although some lineages such as PAAD and MESO show a favorable association.

STAD, BLCA, and PAAD are the cancer types where PCDHB5 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.508	0.648	.001	49	view →
BLCA	DFS	Quartile	II,III,IV	0.507	0.684	.001	46	view →
PAAD	OS	Quartile	All	0.746	0.467	.015	32	view →
MESO	DFS	Median	All	0.445	0.281	.004	26	view →
ESCA	DFS	Median	All	0.918	0.495	.012	22	view →
OV	DFS	Tertile	II,III,IV	0.433	0.333	.012	20	view →
CHOL	OS	Quartile	All	0.380	0.885	.015	19	view →
CESC	DFS	Tertile	All	0.763	0.873	.004	18	view →
UVM	DFS	Tertile	All	0.327	0.718	.012	15	view →
COAD	DFS	Tertile	All	0.724	0.804	.014	12	view →
LIHC	DFS	Quartile	All	0.199	0.382	.005	11	view →
DLBC	DFS	Median	IV	0.120	0.827	.025	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

PCDHB5–STAD (OS)

Open the STAD breakdown →